Related Experiment Video
Updated: Jun 2, 2026
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
Amphiregulin is a potent mitogen in human pancreatic-cancer cells - correlation with patient survival
M Yokoyama1, M Ebert, H Funatomi
1UNIV CALIF IRVINE,DEPT MED,DIV ENDOCRINOL DIABET & METAB,IRVINE,CA 92717. UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717. UNIV BERN,INSELSPITAL,DEPT VISCERAL & TRANSPLANTAT SURG,CH-3010 BERN,SWITZERLAND. US FDA,DIV CYTOKINE BIOL,CELL BIOL LAB,BETHESDA,MD 20892.
Abstract:
The epidermal growth factor (EGF) receptor (EGFR) is activated by EGF and other EGF-like growth factors, including amphiregulin (AR). We characterized the localization and mitogenic action of AR in T3M4 and COLO-357 human pancreatic cancer cell lines and determined whether the presence of AR in human pancreatic cancers correlates with patient survival. Both T3M4 and COLO-357 cells were found to be extremely sensitive to AR, one-half maximal stimulation occurring at a concentration of 70 and 50 pM, respectively. The magnitude of the stimulatory effect was greater with AR than with EGF. Both cell lines exhibited AR immunostaining, which was present in a variable manner in the cytoplasm, nucleus and nucleoli. Immunohistochemical analysis of 62 pancreatic cancer tissues revealed the presence of nuclear and/or cytoplasmic AR immunoreactivity in the cancer cells. Cytoplasmic, but not nuclear localization of AR in the pancreatic cancer cells was associated with a statistically significant decrease in the post-operative survival period. The presence of EGFR alone in the cancer cells did not correlate with decreased survival, whereas coexpression of cytoplasmic AR and EGFR was associated with shorter survival. Distant metastases did not always exhibit cytoplasmic AR immunoreactivity. These findings point to the existence of an EGFR: AR autocrine loop in human pancreatic cancer which may contribute to its biological aggressiveness.
Insights
Amphiregulin (AR) drives pancreatic cancer growth and aggressiveness. Cytoplasmic AR, especially with epidermal growth factor receptor (EGFR), significantly shortens patient survival, indicating a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The epidermal growth factor receptor (EGFR) pathway is crucial in cancer development.
- Amphiregulin (AR) is an EGF-like growth factor that activates EGFR.
- The role of AR in pancreatic cancer progression and patient survival is not fully understood.
Purpose of the Study:
- To investigate the localization and mitogenic effects of AR in human pancreatic cancer cell lines.
- To determine the correlation between AR presence and patient survival in pancreatic cancer.
- To explore the relationship between AR, EGFR, and pancreatic cancer aggressiveness.
Main Methods:
- Characterization of AR localization and mitogenic action in T3M4 and COLO-357 pancreatic cancer cell lines.
- Immunohistochemical analysis of AR expression in 62 human pancreatic cancer tissues.
- Statistical analysis to correlate AR localization (cytoplasmic, nuclear) and EGFR coexpression with patient survival.
Main Results:
- Pancreatic cancer cell lines (T3M4, COLO-357) showed high sensitivity to AR, with greater stimulation than EGF.
- AR immunoreactivity was detected in the cytoplasm, nucleus, and nucleoli of cancer cells.
- Cytoplasmic AR localization, but not nuclear, significantly correlated with decreased post-operative survival.
- Coexpression of cytoplasmic AR and EGFR was associated with shorter survival periods.
Conclusions:
- An autocrine loop involving EGFR and AR may drive the biological aggressiveness of human pancreatic cancer.
- Cytoplasmic AR expression is a potential biomarker for poor prognosis in pancreatic cancer patients.
- Targeting the EGFR:AR pathway could offer a therapeutic strategy for aggressive pancreatic cancers.
